8-K: Ginkgo Bioworks Cuts Losses, Boosts Cell Engineering

Ginkgo Bioworks reports reduced Q2 2025 net loss and improved Adjusted EBITDA, driven by significant cost savings, despite a slight dip in total revenue.

Summary

• Total revenue for the second quarter ended June 30, 2025, was $50 million, down from $56 million in the comparable prior year period.
• Cell Engineering revenue increased 8% to $39 million in Q2 2025 from $36 million in Q2 2024, primarily driven by growth with biopharma and government customers.
• Biosecurity revenue decreased to $10 million in Q2 2025 from $20 million in the comparable prior year period.
• GAAP net loss significantly improved to $(60) million in Q2 2025, compared to $(217) million in the comparable prior year period.
• Adjusted EBITDA improved to $(28) million in Q2 2025, up from $(99) million in the comparable prior year period, attributed to a decrease in operating expenses.
• Cash, cash equivalents, and marketable securities balance as of June 30, 2025, was $474 million.
• The company achieved its $250 million annualized cost-reduction goal three months ahead of schedule through reductions in force and other cost-cutting measures.
• Full year 2025 Total revenue outlook is reaffirmed at $167-$187 million.
• Full year 2025 Cell Engineering revenue outlook is reaffirmed at $117-$137 million.
• Full year 2025 Biosecurity revenue is expected to be at least $40 million.

Sentiment

Score: 7

Explanation: The significant improvement in net loss and Adjusted EBITDA, coupled with achieving cost-reduction targets ahead of schedule, indicates strong operational improvements and financial discipline. While total revenue saw a slight dip, the growth in Cell Engineering revenue and strategic new offerings are positive signs for future growth. The reaffirmed full-year guidance also provides stability.

Positives

• Cell Engineering revenue increased 8% year-over-year to $39 million, driven by growth with biopharma and government customers.
• GAAP net loss significantly reduced to $(60) million from $(217) million in the comparable prior year period, indicating substantial improvement in profitability.
• Adjusted EBITDA improved substantially to $(28) million from $(99) million in the comparable prior year period, reflecting enhanced operational efficiency.
• Achieved the $250 million annualized cost-reduction goal three months ahead of schedule, demonstrating effective financial discipline.
• Launched new offerings, including an in vitro ADME profiling Service built on its proprietary RAC automation system and a direct-to-scientist cell-free protein synthesis system.
• Secured major new government contracts, such as with Pacific Northwest National Laboratory (PNNL) for a state-of-the-art automated anaerobic phenotyping platform.
• Progressing towards the objective of reaching Adjusted EBITDA breakeven by the end of 2026.

Negatives

• Total revenue decreased to $50 million from $56 million in the comparable prior year period.
• Biosecurity revenue declined significantly to $10 million from $20 million in the comparable prior year period.
• The company continues to operate at a net loss and negative Adjusted EBITDA.
• Cash, cash equivalents, and marketable securities decreased from $605.7 million at December 31, 2024, to $474 million at June 30, 2025.

Risks

• Ability to realize near-term and long-term cost savings associated with site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities.
• Volatility in the price of securities due to a variety of factors, including changes in the competitive and highly regulated industries in which the company operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting the business.
• Ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to solutions and tools offerings.
• Risk of downturns in demand for products using synthetic biology.
• Uncertainty regarding the demand for passive monitoring programs and biosecurity services.
• Changes to the biosecurity industry, including due to advancements in technology, emerging competition, and evolution in industry demands, standards, and regulations.
• The outcome of any pending or potential legal proceedings against the company.
• Ability to realize the expected benefits from and the success of the Foundry platform programs and Codebase assets.
• Ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables.
• The product development, production, or manufacturing success of customers.
• Exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration received for services.
• The potential negative impact on the business of restructuring or the failure to realize the anticipated savings associated therewith.
• Uncertainty regarding government budgetary priorities and funding allocated to government agencies.

Future Outlook

The company reaffirms its full year 2025 total revenue outlook of $167-$187 million, with Cell Engineering revenue expected to be $117-$137 million and Biosecurity revenue at least $40 million. It continues to progress towards its objective of reaching Adjusted EBITDA breakeven by the end of 2026.

Management Comments

• Our platform is proving to be a critical engine for AI in biology, with growing demand for our automation and data generation capabilities.
• This is translating into commercial traction, including major new government contracts and expanded service offerings in response to demand in the biopharma industry.
• This progress is backed by rigorous financial discipline, allowing us to achieve our $250 million annualized cost-reduction goal three months ahead of schedule.

Industry Context

The company positions its platform as a critical engine for AI in biology, leveraging automation and data generation capabilities. It is expanding its service offerings in the biopharma industry, including preclinical R&D analytical services, and aims to be a differentiated US-based partner in this space. The biosecurity segment faces evolving demands and competition.

Comparison to Industry Standards

• The new in vitro ADME profiling Service is designed for scale and efficiency, delivering assay quality at cost-effective pricing with a price-matching guarantee, enabling customers to profile more compounds earlier, accelerate decision-making, train AI/ML models, and reduce costs while protecting valuable IP.
• The automated anaerobic phenotyping platform delivered to Pacific Northwest National Laboratory (PNNL) is believed to be the largest automated anaerobic system for research in the world, highlighting a leading capability in this specialized automation.
• The launch of a direct-to-scientist cell-free protein synthesis system, optimized for high production from linear DNA, increased solubility of difficult-to-express proteins, and compatibility with automation, strengthens its position in providing advanced bioengineering tools.
• The company aims to be a differentiated US-based partner in preclinical R&D analytical services for small molecule drug development, emphasizing onshore execution and intellectual property protection.

Legal Proceedings

• The outcome of any pending or potential legal proceedings against the company is identified as a risk factor.
• Securities litigation costs are included in merger and acquisition related expenses.

Related Party Transactions

• Deferred revenue includes $28.287 million (current) and $74.566 million (non-current) from related parties as of June 30, 2025.
• Cell Engineering revenue includes $0.420 million for the three months ended June 30, 2025, and $8.518 million for the six months ended June 30, 2025, from related parties.

Stakeholder Impact

• Shareholders: Improved financial metrics (reduced losses, better EBITDA) and reaffirmed guidance could positively impact investor confidence, though revenue decline in Biosecurity and overall total revenue might be a concern. Cost savings and progress towards breakeven are positive indicators.
• Employees: Reductions in force were part of the cost-cutting measures, impacting some employees.
• Customers: New service offerings (ADME profiling, cell-free protein synthesis) and new government contracts (PNNL) indicate expanded capabilities and value for customers.

Next Steps

• Host a videoconference on Thursday, August 7, 2025, at 5:30 p.m. ET, to provide an overview of the second quarter of 2025, recent business updates, and a discussion on the company's outlook.
• Continue progress towards achieving Adjusted EBITDA breakeven by the end of 2026.

Key Dates

Recommendation

While Ginkgo Bioworks demonstrated significant progress in cost reduction and improved profitability metrics (net loss and Adjusted EBITDA) in Q2 2025, the overall revenue declined, primarily due to a substantial drop in Biosecurity revenue. The growth in Cell Engineering is positive, and achieving cost targets ahead of schedule is commendable. However, the company is still operating at a loss, and the cash burn is notable. The reaffirmed full-year guidance provides some stability. For a seasoned investor, the current situation suggests a 'hold' as the company executes its strategy towards Adjusted EBITDA breakeven by late 2026. The long-term potential in AI-powered biology and biosecurity remains, but the path to consistent profitability and revenue growth needs further demonstration.

Keywords

Ginkgo Bioworks, Cell Programming, Biosecurity, Synthetic Biology, Biopharma, AI in Biology, Biotechnology, Genomics, Automated Lab, Drug Discovery, Preclinical R&D, Cost Reduction, Earnings Report, Q2 2025